Cardioselective beta-blockers for chronic obstructive pulmonary disease: A meta-analysis

Respiratory Medicine

Volumn 97, Issue 10, 2003, Pages 1094-1101

  Salpeter, S R ^a,b   Ormiston, T M ^b   Salpeter, E E ^c   Poole, P J ^d   Cates, C J ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e Bushey Health Center   (United Kingdom)

Author keywords

Beta2 agonist; Cardioselective beta blockers; Chronic obstructive pulmonary disease

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; CELIPROLOL; METOPROLOL; PLACEBO; PRACTOLOL;

CARDIOSELECTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DATA BASE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EMBASE; FORCED EXPIRATORY VOLUME; HEART FAILURE; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; REVIEW; SYMPTOMATOLOGY;

EID: 0141725727     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)00168-9     Document Type: Review

References (74)

1. Abraham TA, Hasan FM, Fenster PE, Marcus FI. Effect of intravenous metoprolol on reversible obstructive airways disease. Clin Pharmacol Ther 1981;29(5):582-7.
2. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997;18:560-5.
3. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999;318:1730-7.
4. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Lee BK, Hlatky MA. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. J Am Med Assoc 1999;281(20):1927-36.
5. The IPPSH Collaborative Group. Cardiovascular risk and risk factors in a randonized trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 1985;3:379-92.
6. JNC VI. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High-Blood Pressure. Arch Intern Med 1997;157:2413-46.
7. Jones M, John R, Jones G. The effect of oxprenolol, acebutolol and propranolol on thyroid hormones in hyperthyroid subjects. Clinical Endocrinology 1980;13:343-7.
8. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol 1997;80(9B): 15J-9J.
9. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994;121(3):281-8.
10. Koch-Weser J. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Eng J Med 1984;310:830-7.
11. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
12. Mangano D, Layug EL, Wallace A, Tateo I. Atenolol reduced mortality and cardiovascular events after noncardiac surgery. N Engl J Med 1996;335:1713-20.
13. Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Eng J Med 1992;327(14):987-92.
14. Wadworth AN, Murdoch D, Brogden RN. Atenolol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991;42(3):468-510.
15. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339(8):489-97.
16. Kennedy HI, Rosenson RS. Physician use of beta-adrenergic blocking therapy: a changing perspective. J Am Coll Cardiol 1995;26(2):547-52.
17. Viskin S, Barron HV. Beta blockers prevent cardiac death following a myocardial infarction: so why are so many infarct survivors discharged without beta blockers? Am J Cardiol 1996;78:821-2.
18. Chafin CC, Soberman JE, Demirkan K, Self T. Beta-blockers after myocardial infarction: do benefits ever outweigh the risks in asthma? Cardiology 1999;92:99-105.
19. Craig T, Richerson HB, Moeckli J. Problem drugs for the patient with asthma. Compr Ther 1996;22(6):339-44.
20. Belli G, Topol EJ. Adjunctive pharmacologic strategies for acute MI. Contemp Intern Med 1995;7(8):51-9.
21. O'Malley K, Cox JP, O'Brien E. Choice of drug treatment for elderly hypertensive patients. Am J Med 1991;90(Suppl 3A):27S-33S.
22. Tattersfield AE. Beta adrenergic antagonists and respiratory disease. J Cardiovasc Pharmacol 1986;8(Suppl 4):S35-9.
23. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther 1990;4:1229-32.
24. Wellstein A, Palm D, Belz G, Butzer R, Polsak R, Pett B. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J 1987;8(Suppl M):3-8.
25. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715-25.
26. Salpeter S, Ormiston T, Salpeter E, Poole P, Cates C. Cardioselective beta-blockers for chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library, Issue 2. Oxford: Update Software: 2002.
27. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995;152(5 Part 2):S77-121.
28. Mantel N, Haenszel WH. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
29. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Progr Cardiovasc Dis 1985;27:335-71.
30. Adam WR, Meagher EJ, Barter CE. Labetalol, beta blockers, and acute deterioration of chronic airway obstruction. Clin Exp Hypertens A 1982;4(8):1419-28.
31. Anderson G, Jariwalla AG, Al-Zaibak M. A comparison of oral metoprolol and propranolol in patients with chronic bronchitis. J Int Med Res 1980;8(2):136-8.
32. Beit M, Ulmer WT. Effects of a new cardioselective beta-adrenergic blocker (atenolol) on airway resistance in chronic obstructive disease. Arzneim-Florsch 1977;27(1):419-22.
33. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986;31(2):143-7.
34. Macquin-Mavier I, Roudot-Thoraval F, Clerici C, George C, Harf A. Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction. Br J Clin Pharmacol 1988;26:279-84.
35. McGavin CR, Williams IP. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 1978;72: 327-32.
36. Perks WH, Chatterjee SS, Croxson RS, Cruilshank JM. Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction. Br J Clin Pharmacol 1978;5:101-6.
37. Schanning J, Vilsvik JS. Beta1-blocker (Practolol) and exercise in patients with chronic obstructive lung disease. Acta Med Scand 1976;199:61-4.
38. Sinclair DJ. Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis. Br Med J 1979;1(6157):168.
39. Sorbini CA, Grassi V, Tantucci C, Todisco T, Motolese M, Verdecchia P. Acute effects of oral metoptolol on ventilatory function in patients with chronic obstructive lung disease. Acta Therap 1982;8:5-16.
40. von Wichert P. Reversibility of bronchospasm in airway obstruction. Am Heart J 1982;104:446-50.
41. Butland RJ, Pang JA, Geddes DM. Effect of beta-adrenergic blockade on hyperventilation and exercise tolerance in emphysema. J Appl Physiol 1983;54(5):1368-73.
42. Dorow P, Clauzel AM, Capone P, Mayol R, Mathieu M. A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction. J Cardiovasc Pharmacol 1986;8(Suppl 4):S102-4.
43. Fenster PE, Hasan FM, Abraham T, Woolfenden J. Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease. Clin Cardiol 1983;6(3): 125-9.
44. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990;4(4):1145-9.
45. Lammers JWJ, Folgerin HTM, van Herwaarden CLA. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. J Clin Pharmac 1985;20:205-10.
46. Ranchod A, Keeton GR, Benatar SR. The effect of beta-blockers on ventilatory function in chronic bronchitis. S Afr Med J 1982;61(12):423-4.
47. Tivenius L. Effects of multiple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease. Scand J Respir Dis 1976;57(4): 190-6.
48. Wunderlich J, Macha HN, Wudicke H, Huckauf H. Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration. Chest 1980;78(5):714-20.
49. Ionnidis JP, Lau J. Pooling research results: benefits and limitations of meta-analysis. Jt Comm J Qual Improv 1999; 25(9):462-9.
50. McNeill RS. Effect of a beta-adrenergic-blocking agent, propranolol, on asthmatics. Lancet 1964;2:1101-2.
51. Zaid G, Beall GN. Bronchial response to beta-adrenergic blockade. New Engl J Med 1966;275:580-4.
52. Anderson EG, Calcraft B, Jariwalla AG, Al-Zaibak M. Persistent asthma after treatment with beta-blocking agents. Br J Dis Chest 1979;73(4):407-8.
53. Raine JM, Palazzo MG, Kerr JH, Sleight P. Near fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br Med J 1981;282: 548-9.
54. Wang TJ, Stafford RS. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med 1998;158:1901-6.
55. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. J Am Med Assoc 1997;277(2):115-21.
56. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med 1994;9:599-605.
57. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blcokers for the treatment of elderly patients after acute myocardial infarction. J Am Med Assoc 1998;280(7):623-9.
58. Heller DA, Ahern FM, Kozak M. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarcion. Am Heart J 2000;140:663-71.
59. George RB, Manocha K, Burford JG, et al. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest 1981;79:540-4.
60. Quan SF, Fenster PE, Hanson CD, et al. Suppression of atrial ectopy with intravenous metoprolol in chronic obstructive pulmonary disease patients. J Clin Pharmacol 1983;23: 341-7.
61. Mooss AN, Hillerman DE, Syed MM, Hunter CB. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann Pharmacother 1994;28: 701-3.
62. Falliers CJ, Vrchota J, Blasucci DJ, et al. The effects of treatment with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. J Clin Hypertens 1985;1(1):70-9.
63. Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol 1976;3:1007-14.
64. Krauss S, Spitz E, Krauss A, et al. Treatment of hypertension in mild asthmatic patients with atenolol. Angiology 1984;Dec:773-8.
65. Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950-6.
66. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-76.
67. Rosenson RS. The truth about beta-blocker adverse effects - depression, claudication, and lipids. J Ambulatory Monit 1993;6(2):163-71.
68. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996;77:1273-7.
69. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50.
70. Wicklmayr M, Rett K, Dietze G, Mehnert H. Effects of beta-blocking agents on insulin secretion and glucose disposal. Horm Metab Res 1990;22(5):29-33.
71. Bright J, Everitt DE. Beta-blockers and depression: evidence against an assoication. J Am Med Assoc 1992;267(13): 1783-7.
72. Beto JA, Bansal VK. Quality of life in treatment of hypertension: a meta-analysis of clinical trials. Am J Hypertens 1992;5(3):125-33.
73. Krumholz HM, Radford MJ, Wang Y, Chen J, Marciniak TA. Early beta-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med. 1999;131(9): 648-54.
74. Opie LH. Required beta blocker profile in the elderly. Cardiovasc Drugs Ther 1990;4:1273-80.